Medical Oncologist and Haematologist
Dr Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As the Section Head for Aggressive B-cell Lymphomas, his research is focused on improving outcomes in relapsed but curable patients using novel therapies. He is the Medical Director at MSK Bergen, directing a team of expert oncologists in the delivery of cutting-edge care across cancer service lines to patients at the free-standing outpatient center in Montvale, New Jersey.
Bayer, Bayer Pharmacyclics, Genentech, GlaxoSmithKline, Immunovaccine Tech, Janssen, Juno Theraputics, Merck, Roche Rocket Medical, Seattle Genetics, Teva and Takeda.
Highlights from the ASH Annual Meeting
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.
Dr. Matthew Matasar provides an update on follicular lymphoma
A review paper ‘Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs’ authored by LYMPHOMA CONNECT members